Supplementary Table 3 ǀ The prognostic importance of ploidy in patients with early stage ovarian
cancer, including BOT
Study (year of
publication)
Dickinson et al.
(2012)S29
Lassus et al.
(2011)S30
Paulsen et al.
(2011)S31
Zeimet et al.
(2011)S32
Akeson et al.
(2009)S33
Veerman et al.
(2009)S34
Verbruggen et
al. (2009)S35
Villella et al.
(2007)S36
Kulkarni et al.
(2007)S37
Kristensen et al.
(2003)S38
Flezar et al.
(2003)S39
Kimmig et al.
(2002)S40
Ozalp et al.
(2001)S41
Skirnisdottir et
al. (2001)S42
Tropè et al.
(2000)S43
Tumour
histology
FIGO
Stage
Diploid
(%)
Follow-up
duration
End
point
P value
HR
Mostly
Ia–Ic
I–IV
70
98 mo
RFS
NS
NS
440
S BOT, Mu
BOT
S
57
8 yrs
M: P = 0.02
1.79
ICMsuspension
ICMsuspension
FCM-A
279
S, Mu, E, CC
I
62
56 mo
U: P <0.01
NA
70
S, Mu
I–IV
NA
NA
M: P = 0.003
2.7
153
III
25
81 mo
NA
1.4
FCM
135
S, Mu, E, CC,
Mx
All
DFS,
OS
DFS,
CSS
RFS,
OS
OS
I–IV
NA
53 mo
PFS,
OS
NA
FCM
93
57 mo
RFS
48
Mostly
I–II
I
91
ICM-section
S BOT, Mu
BOT
G
U: P = 0.012
(PFS)
U: P = 0.024
(OS)
M: NS
NS
?
11 yrs
OS
U: P = 0.019
NA
ICMsuspension
ICMsuspension
ICMsuspension
FCM-A
FCM-F
62
S, E, Mu, CC
I–II
NA
33 mo
M: P = 0.04
4.58
284
I
57
13.2 yrs
M: P <0.0001
9.1
43
S, Mu, E,
CC, Mx
S BOT
I–III
95
6 yrs
DFS,
OS
RFS,
DFS
DSS,
OS
NS
NS
62
S, Mu, E, CC
Mostly
III
NA
21.5 mo
RFS
M: P = 0.03
FCM-F
26
Mostly S
I–IV
38
NA
U: P <0.05
FCM-A
103
All
Ia–IIc
NA
74 mo
RFS,
OS
RFS
3.0
In
FIGO
III
NA
NS
NS
FCM-A
162
S, Mu, E,
CC, Mx
I
45
4 yrs
DFS,
DSS
M: P = 0.003
6.0
Method of
ploidy
measurement
FCM-A
Number
of
patients
70
FCM-A
Abbreviations: BOT, borderline ovarian tumour; CC, clear cell; CSS, cancer-specific survival; DFS,
disease-free survival; DSS, disease-specific survival; E, endometrioid; FCM, flow cytometry; FCM-A,
flow cytometry using archival material; FCM-F, flow cytometry using fresh or frozen material; G,
granulosa cell; HR, hazard ratio; ICM, image cytometry; M, multivariate analysis; mo, month; Mu,
mucinous; Mx, mixed; NA, not applicable/available; NS, not significant; OS, overall survival; PFS,
progression-free survival; RFS, recurrence-free survival; S, serous; U, univariate analysis; yrs, years.
S29.
S30.
S31.
Dickinson, P.D., Chan, S.Y. & Sundar, S. The clinical usefulness of DNA aneuploidy in
borderline ovarian tumours. Onkologie 35, 607 (2012).
Lassus, H., Staff, S., Leminen, A., Isola, J. & Butzow, R. Aurora-A overexpression and
aneuploidy predict poor outcome in serous ovarian carcinoma. Gynecol. Oncol. 120, 11-17
(2011).
Paulsen, T., Kaern, J. & Trope, C. Improved 5-year disease-free survival for FIGO stage I
epithelial ovarian cancer patients without tumor rupture during surgery. Gynecol. Oncol.
122, 83-88 (2011).
NS
S32.
S33.
S34.
S35.
S36.
S37.
S38.
S39.
S40.
S41.
S42.
S43.
Zeimet, A.G. et al. DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in
ovarian cancer. Gynecol. Oncol. 121, 24-31 (2011).
Akeson, M. et al. A population-based 5-year cohort study including all cases of epithelial
ovarian cancer in western Sweden: 10-year survival and prognostic factors. Int.J
Gynecol.Cancer 19, 116-123 (2009).
Veerman, M.M. et al. Clinical value of morphometric and DNA flow cytometric variables as
independent predictors of survival in epithelial ovarian carcinoma: a 5-year follow-up study.
Int. J. Gynecol. Pathol. 28, 432-441 (2009).
Verbruggen, M.B. et al. The prognostic and clinical value of morphometry and DNA
cytometry in borderline ovarian tumors: a prospective study. Int. J. Gynecol. Pathol. 28, 3540 (2009).
Villella, J. et al. Clinical and pathological predictive factors in women with adult-type
granulosa cell tumor of the ovary. Int.J Gynecol.Pathol. 26, 154-159 (2007).
Kulkarni, A.A. et al. DNA replication licensing factors and aurora kinases are linked to
aneuploidy and clinical outcome in epithelial ovarian carcinoma. Clin. Cancer Res. 13, 61536161 (2007).
Kristensen, G.B. et al. Large-scale genomic instability predicts long-term outcome for women
with invasive stage I ovarian cancer. Ann.Oncol. 14, 1494-1500 (2003).
Flezar, M.S., But, I., Kavalar, R. & Us-Krasovec, M. Flow and image cytometric DNA ploidy,
including 5c exceeding cells, of serous borderline malignant ovarian tumors. Correlation with
clinicopathologic characteristics. Anal.Quant.Cytol.Histol. 25, 139-145 (2003).
Kimmig, R. et al. Multivariate analysis of the prognostic significance of DNA-ploidy and Sphase fraction in ovarian cancer determined by flow cytometry following detection of
cytokeratin-labeled tumor cells. Gynecol. Oncol. 84, 21-31 (2002).
Ozalp, S., Yalcin, O.T., Gulbas, Z., Tanir, H.M. & Minsin, T. Effect of cellular DNA content on
the prognosis of epithelial ovarian cancers. Gynecol. Obstet. Invest. 52, 93-97 (2001).
Skirnisdottir, I., Sorbe, B., Karlsson, M. & Seidal, T. Prognostic importance of DNA ploidy and
p53 in early stages of epithelial ovarian carcinoma. Int. J. Oncol. 19, 1295-1302 (2001).
Trope, C. et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian
cancer with evaluation of DNA-ploidy as prognostic instrument. Ann.Oncol. 11, 281-288
(2000).